Developing an Erythromycin Ophthalmic Ointment: Putting the Puzzle Pieces Together
Download in electronic PDF format for $75
Abstract: With the development of new treatment options and reported side effects with the use of silver nitrate ophthalmic solution, the drug manufacturers discontinued production of the silver nitrate ophthalmic solution in the mid 1990s. On December 9, 2009, the U.S. Food and Drug Administration announced that the erythromycin ophthalmic ointment 1-gram tubes were commercially available again and production by the manufacturer was expected to meet the historical demands. Hospitals could expect to replenish their inventory reserves after the first quarter of 2010. However, manufacturer backorders have been increasing due to a variety of factors. If a hospital has a compounding laboratory, it is possible to prepare erythromycin ophthalmic ointment according to the United States Pharmacopeia Chapter <797> standards. Since the commercial product has been available for decades without any major shortages until 2009, there isn’t any published compounding information on how to prepare the ointment. This article discusses t
Related Keywords:
Linda F. McElhiney, PharmD, RPh, FIACP, FASHP, gonococcal ophthalmia neonatorum, neonatal blindness, newborns, erythromycin ophthalmic ointment, prophylaxis, drug shortage, treatment alternatives, topical antibiotic, intraocular antimicrobial, ocular administration, eye infection, formulation
Related Categories:
FORMULATIONS, OPHTHALMICS, PEDIATRICS, STERILE PREPARATIONS, DOSAGE FORMS/DRUG CARRIERS, INFECTIOUS DISEASE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Developing an Erythromycin Ophthalmic Ointment: Putting the Puzzle Pieces Together
McElhiney Linda F
|
Jul/Aug 2010
Pg. 270-274
|
Compounding for the Effects of Weapons of Mass Destruction
Sammarco Domenic A
|
Jan/Feb 2003
Pg. 10-15
View Sample |
Basics of Sterile Compounding: Ophthalmic Preparations, Part 2: Suspensions and Ointments
Allen Loyd V Jr
|
Nov/Dec 2016
Pg. 495-500
|
Erythromycin 1% and Neomycin Sulfate Ointment
Allen Loyd V Jr
|
Mar/Apr 2008
Pg. 153
|
Ointment Vehicles, Featured Excipient:
Allen Loyd V Jr
|
Mar/Apr 2001
Pg. 145-146
|
Dexamethasone 0.1%, Neomycin 0.35%, and Polymixin 10,000 Units/g Ophthalmic Ointment
Allen Loyd V Jr
|
May/Jun 2016
Pg. 228
|
Dexamethasone, Neomycin, and Polymyxin Ophthalmic Ointment
Allen Loyd V Jr
|
Jan/Feb 2016
Pg. 51
|
Erythromycin 50-mg/mL Injection
Allen Loyd V Jr
|
Jan/Feb 2015
Pg. 64
|
Tetracycline HCl 1% Ophthalmic Ointment
Allen Loyd V Jr
|
May/Jun 2001
Pg. 212
|
Erythromycin and Dexamethasone Ophthalmic Solution
Allen Loyd V Jr
|
Nov/Dec 2002
Pg. 452
|
Dexamethasone Phosphate 0.05% Ophthalmic Ointment
Allen Loyd V Jr
|
May/Jun 2003
Pg. 215
|
Bacitracin 500-U/g Ophthalmic Ointment
Allen Loyd V Jr
|
Nov/Dec 2003
Pg. 467
|
I See Colors: Using Vital Dyes in Diagnosing Ophthalmic Disease
McElhiney Linda F
|
May/Jun 2012
Pg. 190-195
|
Three Fortified Ophthalmic Solutions: Amikacin 5% Ophthalmic Solution; Ceftazidime 5% Ophthalmic Solution; Vancomycin 5% Ophthalmic Solution
Allen Loyd V Jr
|
Sep/Oct 2010
Pg. 421
|
Basics of Sterile Compounding: Ophthalmic Preparations, Part 1: Ophthalmic Solutions
Allen Loyd V Jr
|
Sep/Oct 2016
Pg. 399-404
|
Medications Discontinued in the United States
Ashworth Lisa D
|
Nov/Dec 2002
Pg. 441-442
|
Glucose 40% Ophthalmic Ointment
Allen Loyd V Jr
|
May/Jun 1998
Pg. 230
|
Treating Inner Ear Disorders with Intratympanic Drug Administration
McElhiney Linda F
|
Jul/Aug 2011
Pg. 302-307
|
PreScription: Discontinued Drugs and Drug Shortages
Allen Loyd V Jr
|
Mar/Apr 2011
Pg. 92
|
PreScription: The International Academy of Compounding Pharmacists Remembers Evelyn Timmons, RPh, FIACP, and George Roentsch, RPh, FIACP
Karolchyk Scott
|
Jan/Feb 2012
Pg. 4
View Sample |
Return to Top |